Lab results are too important to go anywhere else

Beaumont Laboratory

MGMT Methylation Status

MGMT, MGMT-Methylation, O6-methylguanine methyltransferase, Glioblastoma Methylation

Specimen Collection Criteria

Collect: Paraffin-embedded tissue. A paraffin block must be submitted. (Slides or paraffin shavings are not acceptable.) Submit formalin-fixed, paraffin-embedded block with corresponding H&E slide. Tissue should be well fixed and well processed. Average tissue size 5.0 mm2.

  • DNA will be assessed for quality. If it is deemed unacceptable, testing will be cancelled with client notification.
  • The specimen must be accompanied by a completed requisition and must contain the patient name, date of birth, collection date, ordering physician, and source of specimen.

Physician Office/Drawsite Specimen Preparation

Maintain paraffin-embedded tissue at room temperature (20-26°C or 68-78.8°F) until transport.

Preparation for Courier Transport

Transport: Paraffin-embedded tissue, at room temperature (20-26°C or 68-78.8°F).

Rejection Criteria

  • Decalcified tissue.
  • Fixatives other than 10% neutral buffered formalin.
  • Improper labeling or inadequate information.


Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): Indefinitely
Refrigerated (2-8°C or 36-46°F): Unacceptable
Frozen (-20°C/-4°F or below): Unacceptable

Specimen Storage in Department Prior to Disposal:

Room Temperature (20-26°C or 68-78.8°F): 7 days


Royal Oak Clinical Molecular Pathology Laboratory.


Monday - Friday.
Results available in 7 business days. 

Reference Range

An interpretive report will be provided.

Test Methodology

Following DNA extraction and bisulfate treatment, molecular analysis of the MGMT gene is performed by methylation-specific Real-Time Polymerase Chain Reaction (PCR) using an ABI 7500 FAST Real-Time PCR Instrument (Applied Biosystems Inc, Foster City, CA).


An interpretive report will be provided.

Clinical Utility

O6-methylguanine methyltransferase (MGMT) promoter methylation status predicts response of glioblastoma cells to alkylating agents. Patients with MGMT-methylated tumors have improved progression-free and overall survival when treated with alkylating agents such as temozolomide. Methylation of MGMT in glioblastomas also predicts a more favorable response to radiotherapy in the absence of alkylating agent therapy.


  1. Hegi ME, Lie L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR. Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation with Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. JClin Oncol. 2008 Sep 1;26(25):4189-99.
  2. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C. Prognostic Value of O(6)-Methylguanine-DNA Methyltransferase Status in Glioblastoma Patients, Assessed by Five Different Methods. J Neurooncol. 2009 Oct 20.
  3. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD. MGMT Promoter Methylation is Predictive of Response to Radiotherapy and Prognostic in the Absence of Adjuvant Alkylating Chemotherapy for Glioblastoma. Neuro Oncol. 2010 Feb; 12(2):116-21. Epub 2009 Dec 14.

CPT Code


Last Updated


Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.